CO2019009525A2 - Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este - Google Patents
Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de esteInfo
- Publication number
- CO2019009525A2 CO2019009525A2 CONC2019/0009525A CO2019009525A CO2019009525A2 CO 2019009525 A2 CO2019009525 A2 CO 2019009525A2 CO 2019009525 A CO2019009525 A CO 2019009525A CO 2019009525 A2 CO2019009525 A2 CO 2019009525A2
- Authority
- CO
- Colombia
- Prior art keywords
- associated virus
- seq
- adeno
- aav
- subtype
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464748P | 2017-02-28 | 2017-02-28 | |
| US201762591002P | 2017-11-27 | 2017-11-27 | |
| US201862614002P | 2018-01-05 | 2018-01-05 | |
| PCT/US2018/019992 WO2018160582A1 (en) | 2017-02-28 | 2018-02-27 | Adeno-associated virus (aav) clade f vector and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019009525A2 true CO2019009525A2 (es) | 2019-09-18 |
Family
ID=61628475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0009525A CO2019009525A2 (es) | 2017-02-28 | 2019-08-30 | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11827906B2 (enExample) |
| EP (2) | EP3589730B1 (enExample) |
| JP (3) | JP7455579B2 (enExample) |
| KR (1) | KR102775350B1 (enExample) |
| CN (2) | CN110741082B (enExample) |
| AU (2) | AU2018227440B2 (enExample) |
| BR (1) | BR112019017839A2 (enExample) |
| CA (1) | CA3053399A1 (enExample) |
| CL (1) | CL2019002474A1 (enExample) |
| CO (1) | CO2019009525A2 (enExample) |
| DK (1) | DK3589730T5 (enExample) |
| ES (1) | ES2971872T3 (enExample) |
| FI (1) | FI3589730T3 (enExample) |
| HR (1) | HRP20240257T1 (enExample) |
| HU (1) | HUE065885T2 (enExample) |
| IL (1) | IL268644B2 (enExample) |
| LT (1) | LT3589730T (enExample) |
| MD (1) | MD3589730T2 (enExample) |
| MX (2) | MX2019010275A (enExample) |
| PE (1) | PE20191362A1 (enExample) |
| PL (1) | PL3589730T3 (enExample) |
| PT (1) | PT3589730T (enExample) |
| RS (1) | RS65241B1 (enExample) |
| SA (1) | SA519402565B1 (enExample) |
| SG (4) | SG10201912973XA (enExample) |
| SI (1) | SI3589730T1 (enExample) |
| SM (1) | SMT202400080T1 (enExample) |
| WO (1) | WO2018160582A1 (enExample) |
| ZA (1) | ZA201905407B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2915124C (en) | 2001-11-13 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US10494645B2 (en) | 2013-04-18 | 2019-12-03 | Fondazione Telethon | Effective delivery of large genes by dual AAV vectors |
| EP3831842A1 (en) | 2015-09-28 | 2021-06-09 | The University of North Carolina at Chapel Hill | Methods and compositions for antibody-evading virus vectors |
| CA3011529A1 (en) * | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| US11827906B2 (en) | 2017-02-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clade f vector and uses therefor |
| RU2019139555A (ru) | 2017-05-11 | 2021-06-11 | Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания | Генная терапия нейрональных цероидных липофусцинозов |
| CA3083761A1 (en) | 2017-11-30 | 2019-06-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for mucopolysaccharidosis iiib |
| JP7389744B2 (ja) | 2017-11-30 | 2023-11-30 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ｉｉｉａ型のための遺伝子療法 |
| EP3758724A4 (en) * | 2018-02-27 | 2022-07-06 | The Trustees of The University of Pennsylvania | NOVEL VECTORS OF ADENO-ASSOCIATED VIRUS (AAV), AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF |
| MX2020008932A (es) | 2018-02-27 | 2020-10-01 | Univ Pennsylvania | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. |
| EP3773743A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| KR20210071017A (ko) * | 2018-10-01 | 2021-06-15 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Gm1 강글리오시드증 치료에 유용한 조성물 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| SG11202108614QA (en) | 2019-02-15 | 2021-09-29 | Sangamo Therapeutics Inc | Compositions and methods for producing recombinant aav |
| EP3927381A1 (en) | 2019-02-22 | 2021-12-29 | The Trustees of The University of Pennsylvania | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration |
| MX2021010266A (es) * | 2019-02-26 | 2021-09-23 | Univ Pennsylvania | Composiciones utiles en el tratamiento de la enfermedad de krabbe. |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| US20220202960A1 (en) * | 2019-04-24 | 2022-06-30 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| PH12021552608A1 (en) * | 2019-04-29 | 2022-06-20 | Univ Pennsylvania | Novel aav capsids and compositions containing same |
| WO2020227166A1 (en) * | 2019-05-03 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療ｃ型尼曼—匹克病之腺相關病毒載體 |
| EP4072572A4 (en) * | 2019-12-10 | 2024-01-03 | Homology Medicines, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021155337A1 (en) | 2020-02-02 | 2021-08-05 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
| CN115287350B (zh) * | 2020-03-30 | 2025-07-04 | 中国医学科学院肿瘤医院 | 包括外泌体miR-106b-3p、miR-10a-3p等在肺癌诊断中的应用 |
| IL297635A (en) * | 2020-04-27 | 2022-12-01 | Univ Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| AU2021270447A1 (en) | 2020-05-12 | 2023-01-05 | The Trustees Of The University Of Pennsylvania | Compositions for DRG-specific reduction of transgene expression |
| TW202208622A (zh) * | 2020-05-12 | 2022-03-01 | 賓州大學委員會 | 用於治療克拉培氏病之組成物 |
| WO2021242909A1 (en) | 2020-05-26 | 2021-12-02 | Shape Therapeutics Inc. | High throughput engineering of functional aav capsids |
| TW202216244A (zh) | 2020-07-13 | 2022-05-01 | 賓州大學委員會 | 有用於治療夏馬杜三氏病之組成物 |
| JP2023536148A (ja) | 2020-07-30 | 2023-08-23 | シェイプ セラピューティクス インク． | Ｒａａｖウイルス粒子の誘導産生のための安定な細胞株 |
| TW202227632A (zh) | 2020-08-19 | 2022-07-16 | 美商史崔德生物公司 | 用於治療雷特症候群之腺相關病毒載體 |
| MX2023002293A (es) | 2020-08-24 | 2023-05-19 | Univ Pennsylvania | Vectores virales que codifican fusiones de agonistas del receptor de glp-1 y usos de estos en el tratamiento de enfermedades metabólica. |
| MX2023002364A (es) | 2020-08-26 | 2023-05-22 | Univ Pennsylvania | Virus adenoasociado recombinante para el tratamiento de la neurodegeneración iniciada en adultos asociada a grn. |
| KR20230118075A (ko) | 2020-10-09 | 2023-08-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 파브리병 치료를 위한 조성물 및 방법 |
| TW202229315A (zh) | 2020-10-18 | 2022-08-01 | 賓州大學委員會 | 改良的腺相關病毒(aav)載體及其用途 |
| CA3199234A1 (en) * | 2020-10-22 | 2022-04-28 | Scout Bio, Inc. | Method of suppressing immune response to vector-delivered therapeutic protein |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| EP4236975A1 (en) * | 2020-10-29 | 2023-09-06 | The Trustees of The University of Pennsylvania | Aav capsids and compositions containing same |
| EP4236974A2 (en) * | 2020-10-29 | 2023-09-06 | RegenxBio Inc. | Vectorized factor xii antibodies and administration thereof |
| TW202233584A (zh) | 2020-11-11 | 2022-09-01 | 歐洲分子生物學實驗室 | 用於基因治療之經修飾病毒顆粒 |
| EP4256065A2 (en) | 2020-12-01 | 2023-10-11 | The Trustees of The University of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
| CA3200192A1 (en) | 2020-12-01 | 2022-06-09 | Justin PERCIVAL | Compositions and uses thereof for treatment of angelman syndrome |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20240191258A1 (en) | 2021-04-12 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating spinal and bulbar muscular atrophy (sbma) |
| EP4334334A1 (en) | 2021-04-23 | 2024-03-13 | The Trustees of The University of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| AU2022274162A1 (en) | 2021-05-12 | 2023-11-30 | Fondazione Telethon | Vector system |
| IL308787A (en) * | 2021-06-08 | 2024-01-01 | Univ Pennsylvania | Recombinant adeno-associated viruses for Leish-Nihan disorders and their uses |
| TW202325845A (zh) | 2021-10-02 | 2023-07-01 | 賓州大學委員會 | 新穎aav衣殼及含其之組成物 |
| US20250295807A1 (en) | 2021-11-15 | 2025-09-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| US20250026795A1 (en) | 2021-12-01 | 2025-01-23 | Shape Therapeutics Inc. | Functional aav capsids for intravitreal administration |
| AU2022401548A1 (en) | 2021-12-01 | 2024-07-04 | Shape Therapeutics Inc. | Functional aav capsids for systemic administration |
| WO2023102517A1 (en) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| WO2023133584A1 (en) | 2022-01-10 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| TW202340467A (zh) | 2022-01-10 | 2023-10-16 | 賓州大學委員會 | 有用於治療c9orf72介導之病症之組成物及方法 |
| IL314434A (en) | 2022-01-25 | 2024-09-01 | Univ Pennsylvania | AAV capsids for enhanced cardiac transduction and liver targeting neutralization |
| CA3247109A1 (en) | 2022-04-06 | 2023-10-12 | Univ Pennsylvania | Compositions and treatment methods for metastatic breast cancer that is human epidermal growth factor receptor 2 positive and other cancers |
| EP4504258A1 (en) | 2022-04-06 | 2025-02-12 | The Trustees of the University of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| US20250353883A1 (en) | 2022-05-06 | 2025-11-20 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
| EP4522757A2 (en) * | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| CN121127599A (zh) | 2022-12-17 | 2025-12-12 | 宾夕法尼亚州大学信托人 | 具有心肌和骨骼肌特异性靶向基序的重组aav突变载体及含有其的组合物 |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| AU2024221161A1 (en) | 2023-02-17 | 2025-08-28 | Biogen Ma Inc. | Rgd-containing peptides for delivering payloads |
| WO2024258961A1 (en) | 2023-06-12 | 2024-12-19 | The Trustees Of The University Of Pennsylvania | Aav gene therapy for mucopolysaccharidosis iiib |
| TW202516019A (zh) | 2023-06-29 | 2025-04-16 | 賓州大學委員會 | 具中樞神經系統靶向模體的突變aav及含有其之組成物 |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025076091A1 (en) * | 2023-10-03 | 2025-04-10 | Brave Bio, Inc. | Cd20 antibody aav vectors and methods of use thereof |
| WO2025090858A1 (en) | 2023-10-27 | 2025-05-01 | Biogen Ma Inc. | Methods for identifying aav capsid variants with desired characteristics |
| WO2025096967A1 (en) | 2023-11-02 | 2025-05-08 | Biogen Ma Inc. | Redirection of aav capsids for central nervous system targeting |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025188625A1 (en) | 2024-03-03 | 2025-09-12 | Passage Bio, Inc. | Recombinant adeno-associated virus for treatment of neurodegenerative disorders |
| WO2025207948A1 (en) | 2024-03-27 | 2025-10-02 | Biogen Ma Inc. | Aav capsids for targeting human transferrin receptor |
| WO2025207932A1 (en) | 2024-03-27 | 2025-10-02 | Biogen Ma Inc. | Aav capsids comprising anti-transferrin antibody domains |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| JPH08506144A (ja) | 1993-02-05 | 1996-07-02 | ラポート グループ オーストラリア リミティド | スラグ脱泡複合材料 |
| US6140120A (en) | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| PL310327A1 (en) | 1993-02-12 | 1995-12-11 | Univ Leland Stanford Junior | Adjustable transcription of target genes and other biological processes |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| US20020173474A1 (en) | 1993-02-12 | 2002-11-21 | President And Fellows Of Harvard College | Methods & materials involving dimerization-mediated regulation of biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
| US6476200B1 (en) | 1994-06-27 | 2002-11-05 | The Johns Hopkins University | Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US6133456A (en) | 1994-08-18 | 2000-10-17 | Ariad Gene Therapeutics, Inc. | Synthetic multimerizing agents |
| US6150527A (en) | 1994-08-18 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Synthetic multimerizing agents |
| EP0776327B1 (en) | 1994-08-18 | 2005-07-06 | Ariad Gene Therapeutics, Inc. | New multimerizing agents |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US6326166B1 (en) | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
| CA2209183A1 (en) | 1994-12-29 | 1996-07-11 | Joel L. Pomerantz | Chimeric dna-binding proteins |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| DE69739853D1 (de) | 1996-02-28 | 2010-06-02 | Ariad Pharma Inc | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
| US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| ATE364718T1 (de) | 1997-04-01 | 2007-07-15 | Solexa Ltd | Verfahren zur vervielfältigung von nukleinsäure |
| DE69824859T2 (de) | 1997-04-14 | 2005-08-04 | Cell Genesys, Inc., Foster City | Methoden zur erhöhung der effizienz rekombinanter aav produkte |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| AU752129B2 (en) | 1997-08-27 | 2002-09-05 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
| AU755784B2 (en) | 1998-01-15 | 2002-12-19 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using multimeric chimeric proteins |
| CA2319492A1 (en) | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US7109317B1 (en) | 1998-11-06 | 2006-09-19 | President And Fellows Of Harvard College | FK506-based regulation of biological events |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| US6780639B1 (en) | 1999-08-24 | 2004-08-24 | Universite Libre De Bruxelles | Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization |
| JP3961737B2 (ja) | 2000-02-29 | 2007-08-22 | 株式会社小糸製作所 | 車両用灯具およびその製造方法 |
| CN1304578C (zh) | 2000-03-22 | 2007-03-14 | 罗姆和哈斯公司 | 新的基于蜕皮激素受体的可诱导的基因表达系统 |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| JP4955905B2 (ja) | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用 |
| JP4328094B2 (ja) | 2001-02-20 | 2009-09-09 | イントレクソン・コーポレイション | 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用 |
| EP1534738B1 (en) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| AU2002247184B2 (en) | 2001-02-20 | 2008-06-19 | Intrexon Corporation | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system |
| EP1392868B2 (en) | 2001-05-18 | 2013-09-04 | Wisconsin Alumni Research Foundation | Method for the synthesis of dna sequences using photo-labile linkers |
| CA2915124C (en) | 2001-11-13 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2602352T3 (es) | 2001-12-17 | 2017-02-20 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas |
| WO2003104413A2 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Production of pseudotyped recombinant aav virions |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| EP1660970A4 (en) | 2003-08-01 | 2007-02-14 | Dna Twopointo Inc | SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US20060246079A1 (en) | 2003-11-14 | 2006-11-02 | Morrow Phillip R | Neutralizing human antibodies to anthrax toxin |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| EP2357010B1 (en) | 2005-04-07 | 2013-06-12 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| US7456683B2 (en) | 2005-06-09 | 2008-11-25 | Panasonic Corporation | Amplitude error compensating device and quadrature skew error compensating device |
| DK2548560T3 (en) | 2005-06-23 | 2015-07-13 | Cold Spring Harbor Lab | Compositions and Methods for Modulating SMN2 Splicing |
| US8877187B2 (en) | 2005-07-25 | 2014-11-04 | Avianax, Llc | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| EP2018421B1 (en) | 2006-04-28 | 2012-12-19 | The Trustees of the University of Pennsylvania | Scalable production method for aav |
| ES2596885T3 (es) | 2006-06-07 | 2017-01-12 | Genzyme Corporation | Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la medula espinal |
| JP2010520748A (ja) | 2007-02-20 | 2010-06-17 | アナプティスバイオ インコーポレイティッド | 体細胞超変異系 |
| JP5346820B2 (ja) | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 |
| CA2684534C (en) | 2007-04-17 | 2017-04-04 | National Research Council Of Canada | Constructs for enhancement of gene expression in muscle |
| US7879326B2 (en) | 2007-06-15 | 2011-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Human neutralizing monoclonal antibodies to H5N1 influenza A virus |
| US7863425B2 (en) | 2007-09-26 | 2011-01-04 | Cornell University | Compositions and methods for inhibiting Yersinia pestis infection |
| CN102089324B (zh) | 2007-11-12 | 2014-04-16 | 特罗科隆科学有限公司 | 用于对流行性感冒进行治疗以及诊断的组合物以及方法 |
| RU2010127156A (ru) | 2007-12-06 | 2012-01-20 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Антитела против вируса гриппа и их применение |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| EP2698380A1 (en) | 2008-03-28 | 2014-02-19 | Sea Lane Biotechnologies, LLC | Neutralizing molecules to viral antigens |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| EP2296700A2 (en) | 2008-06-03 | 2011-03-23 | Vaxin, Inc. | Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens |
| CN102216327A (zh) | 2008-07-25 | 2011-10-12 | 生物医学研究所 | 中和抗甲型流感病毒抗体及其用途 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| US8211631B2 (en) | 2008-12-18 | 2012-07-03 | Wisconsin Alumni Research Foundation | In vitro model of spinal muscular atrophy |
| WO2010071832A1 (en) | 2008-12-19 | 2010-06-24 | Nationwide Children's Hospital | Delivery of polynucleotides across the blood brain barrier using recombinant aav9 |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| IT1395961B1 (it) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
| SI3449926T1 (sl) | 2009-06-17 | 2020-04-30 | Biogen Ma Inc. | Sestave in metode za modulacijo združevanja SMN2 pri subjektu |
| WO2010151673A1 (en) | 2009-06-25 | 2010-12-29 | Medimmune, Llc | Swine influenza hemagglutinin variants |
| US8598331B2 (en) | 2009-09-28 | 2013-12-03 | The University Of British Columbia | CLDN5 mini-promoters |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| SG10201502270TA (en) | 2010-03-29 | 2015-05-28 | Univ Pennsylvania | Pharmacologically induced transgene ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| WO2012145572A1 (en) | 2011-04-20 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
| WO2012145759A2 (en) | 2011-04-21 | 2012-10-26 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Methods of protein production and compositions thereof |
| US20140206753A1 (en) | 2011-06-08 | 2014-07-24 | Shire Human Genetic Therapies, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| JP5683752B2 (ja) | 2011-07-14 | 2015-03-11 | クルセル ホランド ベー ヴェー | 系統グループ１及び系統グループ２のインフルエンザａ型ウイルス、並びにインフルエンザｂ型ウイルスを中和することが可能なヒト結合分子 |
| JP6170507B2 (ja) | 2012-01-31 | 2017-07-26 | 国立大学法人大阪大学 | Ｂ型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法 |
| EA028433B1 (ru) | 2012-03-08 | 2017-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитело, связывающееся с вирусами гриппа b и его применение |
| WO2013155222A2 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Brain-specific enhancers for cell-based therapy |
| WO2013182683A1 (en) | 2012-06-08 | 2013-12-12 | Ethris Gmbh | Pulmonary delivery of messenger rna |
| CN104704123A (zh) | 2012-06-21 | 2015-06-10 | 肌肉学研究协会 | 基因治疗载体的广泛的基因递送 |
| ES2791778T3 (es) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4 |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| AU2013388083B2 (en) | 2013-05-01 | 2019-08-22 | Genzyme Corporation | Compositions and methods for treating spinal muscular atrophy |
| KR20170047192A (ko) | 2014-02-19 | 2017-05-04 | 조디 베리 | 에볼라 단클론성 항체 |
| WO2015164778A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennysylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
| US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| WO2015164757A1 (en) * | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| SG11201609207SA (en) | 2014-05-13 | 2016-12-29 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
| EP3800260A1 (en) * | 2014-09-24 | 2021-04-07 | City of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| WO2016054598A2 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| JP6772157B2 (ja) | 2015-02-05 | 2020-10-21 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | インフルエンザヘマグルチニンに対する結合分子及びその使用 |
| CN108135994B (zh) | 2015-05-13 | 2022-01-25 | 宾夕法尼亚州大学信托人 | Aav-介导的抗-流感抗体的表达及其使用方法 |
| WO2017075119A1 (en) | 2015-10-28 | 2017-05-04 | The Trustees Of The Univeresity Of Pennsylvania | Intrathecal administration of adeno-associated-viral vectors for gene therapy |
| WO2017100674A1 (en) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav1 |
| ES2934848T3 (es) | 2015-12-11 | 2023-02-27 | Univ Pennsylvania | Método de purificación escalable para AAV8 |
| WO2017100704A1 (en) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aavrh10 |
| WO2017160360A2 (en) | 2015-12-11 | 2017-09-21 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| US20190002915A1 (en) | 2015-12-14 | 2019-01-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulatable antibody expression |
| WO2017106326A1 (en) | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
| JP7082050B2 (ja) | 2015-12-14 | 2022-06-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脊髄性筋萎縮症の処置において有用なアデノ－関連ウイルスベクター |
| US10973929B2 (en) | 2016-02-03 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type I |
| CN110168080B (zh) * | 2016-08-15 | 2024-05-31 | 建新公司 | 检测aav的方法 |
| WO2018057916A1 (en) | 2016-09-24 | 2018-03-29 | The Trustees Of The University Of Pennsylvania | Novel humanized anti-ebola antibodies useful in preventing ebola infections |
| SG11201907611WA (en) * | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
| US11827906B2 (en) | 2017-02-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clade f vector and uses therefor |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
-
2018
- 2018-02-27 US US16/487,674 patent/US11827906B2/en active Active
- 2018-02-27 SG SG10201912973XA patent/SG10201912973XA/en unknown
- 2018-02-27 AU AU2018227440A patent/AU2018227440B2/en active Active
- 2018-02-27 SG SG10201912976WA patent/SG10201912976WA/en unknown
- 2018-02-27 KR KR1020197027807A patent/KR102775350B1/ko active Active
- 2018-02-27 SI SI201831066T patent/SI3589730T1/sl unknown
- 2018-02-27 SG SG11201907714UA patent/SG11201907714UA/en unknown
- 2018-02-27 BR BR112019017839A patent/BR112019017839A2/pt unknown
- 2018-02-27 HR HRP20240257TT patent/HRP20240257T1/hr unknown
- 2018-02-27 IL IL268644A patent/IL268644B2/en unknown
- 2018-02-27 PE PE2019001786A patent/PE20191362A1/es unknown
- 2018-02-27 PL PL18711202.4T patent/PL3589730T3/pl unknown
- 2018-02-27 HU HUE18711202A patent/HUE065885T2/hu unknown
- 2018-02-27 WO PCT/US2018/019992 patent/WO2018160582A1/en not_active Ceased
- 2018-02-27 EP EP18711202.4A patent/EP3589730B1/en active Active
- 2018-02-27 CN CN201880028016.XA patent/CN110741082B/zh active Active
- 2018-02-27 SG SG10201912969XA patent/SG10201912969XA/en unknown
- 2018-02-27 RS RS20240217A patent/RS65241B1/sr unknown
- 2018-02-27 EP EP23183607.3A patent/EP4272765A3/en active Pending
- 2018-02-27 JP JP2019547088A patent/JP7455579B2/ja active Active
- 2018-02-27 DK DK18711202.4T patent/DK3589730T5/da active
- 2018-02-27 LT LTEPPCT/US2018/019992T patent/LT3589730T/lt unknown
- 2018-02-27 FI FIEP18711202.4T patent/FI3589730T3/fi active
- 2018-02-27 SM SM20240080T patent/SMT202400080T1/it unknown
- 2018-02-27 MX MX2019010275A patent/MX2019010275A/es unknown
- 2018-02-27 CN CN202411106261.1A patent/CN118956781A/zh active Pending
- 2018-02-27 CA CA3053399A patent/CA3053399A1/en active Pending
- 2018-02-27 MD MDE20200060T patent/MD3589730T2/ro unknown
- 2018-02-27 PT PT187112024T patent/PT3589730T/pt unknown
- 2018-02-27 ES ES18711202T patent/ES2971872T3/es active Active
-
2019
- 2019-08-15 ZA ZA201905407A patent/ZA201905407B/en unknown
- 2019-08-27 CL CL2019002474A patent/CL2019002474A1/es unknown
- 2019-08-28 SA SA519402565A patent/SA519402565B1/ar unknown
- 2019-08-28 MX MX2024012403A patent/MX2024012403A/es unknown
- 2019-08-30 CO CONC2019/0009525A patent/CO2019009525A2/es unknown
-
2023
- 2023-04-12 JP JP2023064895A patent/JP7754872B2/ja active Active
- 2023-10-11 US US18/484,856 patent/US20240117322A1/en active Pending
-
2024
- 2024-09-04 AU AU2024219391A patent/AU2024219391A1/en active Pending
-
2025
- 2025-02-20 JP JP2025025694A patent/JP2025081544A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019009525A2 (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este | |
| CO2020004738A2 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| CL2020002201A1 (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidación reducida de la cápside y usos de estos. | |
| CL2022003757A1 (es) | Vectores de aav que tienen una desamidación reducida de la cápside y sus usos (divisional solic 202002200). | |
| CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| ZA202004980B (en) | A modified raav capsid protein for gene therapy | |
| MX2021012311A (es) | Variantes de capsides de aav para liberacion intravitrea. | |
| MX388331B (es) | Variantes de virus adenoasociado y métodos de uso de estas | |
| ES2629380T3 (es) | Viriones de AAV con inmunorreactividad reducida y usos de los mismos | |
| UY37620A (es) | Vacunas contra la gripe mediadas por aav novedosas | |
| RU2017142006A (ru) | Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| EA201791936A1 (ru) | Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основе | |
| CO2020002283A2 (es) | Métodos de terapia génica del factor viii (fviii) | |
| PH12022550109A1 (en) | Modified aav capsid proteins for treatment of arthritic disease | |
| PE20221254A1 (es) | Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma | |
| CO2024006328A2 (es) | Composiciones útiles en el tratamiento del trastorno por deficiencia de cdkl5 (cdd) | |
| MX2022000038A (es) | Virus del dengue atenuados. | |
| MX2021008832A (es) | Composiciones y metodos para la administracion de polipeptidos cftr. | |
| CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
| EA201992023A1 (ru) | Вектор на основе аденоассоциированного вируса (aav) клады f и его применения | |
| PE20241345A1 (es) | Proteina vp1 modificada y aislada de la capside del virus adenoasociado del serotipo 5 (aav5), capside y vector basados en esta | |
| WO2023250447A3 (en) | Methods of selection and use of engineered cyclic peptides for enhancing viral production |